MiNK Therapeutics (NASDAQ:INKT) Given New $35.00 Price Target at HC Wainwright

MiNK Therapeutics (NASDAQ:INKT) had its target price increased by analysts at HC Wainwright from $9.00 to $35.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 228.64% from the company’s current price.

Separately, Robert W. Baird cut their price target on MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating for the company in a report on Friday, November 15th.

MiNK Therapeutics Trading Up 5.4 %

INKT stock opened at $10.65 on Tuesday. The firm has a 50-day moving average of $8.29 and a two-hundred day moving average of $7.71. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $19.00. The company has a market cap of $42.17 million, a price-to-earnings ratio of -2.73 and a beta of 0.17.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.